A/Prof Ken Sikaris - Sonic Healthcare - Impact of the diabetes epidemic and changing guidelines on...

Post on 17-Jan-2015

343 views 6 download

Tags:

description

A/Prof Ken Sikaris delivered the presentation at 2014 National Pathology Forum. The National Pathology Forum 2014 featured case studies on innovative testing methods in the fields of genetics, biobanking and PoCT. The highly interactive nature of the National Pathology Forum allowed delegates to network with each other and converse with the speakers asking questions as part of debates, industry roundtables, short workshops and panel discussions. For more information about the event, please visit: http://bit.ly/pathology14

Transcript of A/Prof Ken Sikaris - Sonic Healthcare - Impact of the diabetes epidemic and changing guidelines on...

A/Prof Ken Sikaris 9th September 2014

Impact of the diabetes epidemic

and changing guidelines

on laboratory workload

A/Prof Ken SikarisDirector of Clinical Support Systems

Sonic Healthcare

BSc(Hons), MBBS, FRCPA, FAACB, FFSc, GAICD

A/Prof Ken Sikaris 9th September 2014

Australia

A/Prof Ken Sikaris 9th September 2014

Diabetes in Australia: 1980 - 2000

0

200

400

600

800

1000

’80 ’82 ’84 ’86 ’88 ’90 ’92 ’94 ’96 ’98 ’00

Th

ou

san

ds

Year

a)

Busselton

b) Nat Heart

Foundation

c) Aust Bureau

Statistics

d) Aust Bureau

Statistics

e) AusDiab

A/Prof Ken Sikaris 9th September 2014

Ausdiab Diabetes Prevalence 1999-2012

A/Prof Ken Sikaris 9th September 2014

Approx 1.5 million today, 3.5 million by 2033.

275 Australians develop type 2 diabetes every day

By 2023 type 2 diabetes is projected to become

the leading specific cause of disease burden for

men and the second leading cause for women.

Diabetes in Australia

A/Prof Ken Sikaris 9th September 2014

A/Prof Ken Sikaris 9th September 2014

A/Prof Ken Sikaris 9th September 2014

ABS Survey 2011-2012

ALL MEN WOMEN

DIABETES Fasting Glucose 5.1% 6.3% 3.9%

HbA1c 5.4% 6.6% 4.2%

PREDIABETES Fasting Glucose 3.1% 4.1% 2.1%

HbA1c 5.4% 5.5% 5.3%

1 in 16 Australians are diabetic

4% reported to have diabetes85% Type 2

12% Type 1

A/Prof Ken Sikaris 9th September 2014

ABS Survey 2011-2012

A/Prof Ken Sikaris 9th September 2014

Diabetes Complications

A/Prof Ken Sikaris 9th September 2014

CVD

(Exp

on

en

tia

l)

A/Prof Ken Sikaris 9th September 2014

Cardiovascular Disease

Diabetes or pre-diabetes

In 65% of CVD

A/Prof Ken Sikaris 9th September 2014

Improving CVD: Statins?

A/Prof Ken Sikaris 9th September 2014

CVD mortality trends

Factors

Smoking

Antihypertensives

Statins

Survival after AMI

Angioplasty

Antithrombotics

A/Prof Ken Sikaris 9th September 2014

Leading Causes of Death

A/Prof Ken Sikaris 9th September 2014

CVD Hospitalisations

A/Prof Ken Sikaris 9th September 2014

CVD Hospitalisations

A/Prof Ken Sikaris 9th September 2014

Improving Diabetes Outcomes

A/Prof Ken Sikaris 9th September 2014

Australian Diabetes Costs

Total Costs

$6.6 billion (2003)

HbA1c $0.01 billion

A/Prof Ken Sikaris 9th September 2014

Cost distribution in Type 2 diabetes

A/Prof Ken Sikaris 9th September 2014

A/Prof Ken Sikaris 9th September 2014

Preventable Health Costs

A/Prof Ken Sikaris 9th September 2014

Diabetic Renal Disease

A/Prof Ken Sikaris 9th September 2014

The Deadly QuartetKaplan Arch Int Med

1989;149:1514-1520

A/Prof Ken Sikaris 9th September 2014

Which one of the

deadly quartet is

missing?

A/Prof Ken Sikaris 9th September 2014

Top tests for diabetes, lipids, HT

A/Prof Ken Sikaris 9th September 2014

BEACH: TYPE 2 DIABETES & GP’s

2000-02 2006-08

GP visits 2.6% 3.3%

Pathology Requests/Visit 63.6% 88.4%

Total Diab Tests 1,700,000 3,100,000

% of all GP pathology 4.9% 6.0%

A/Prof Ken Sikaris 9th September 2014

A/Prof Ken Sikaris 9th September 2014

http://www.medicareaustralia.gov.au/statistics/mbs_item.shtml

A/Prof Ken Sikaris 9th September 2014

MBS Schedule 66608: Vitamin D

A/Prof Ken Sikaris 9th September 2014

MBS Schedule 66608: Vitamin D

A/Prof Ken Sikaris 9th September 2014

MBS Schedule 66551: HbA1c

About $16 million / annum* (50% coned)

A/Prof Ken Sikaris 9th September 2014

MBS Schedule 2517: Diabetes PIP

A/Prof Ken Sikaris 9th September 2014

MBS Schedule 10951: Diabetes Education

A/Prof Ken Sikaris 9th September 2014

MBS Schedule 717: 45y/o Health Check

A/Prof Ken Sikaris 9th September 2014

MBS Schedule 66536: HDLC

A/Prof Ken Sikaris 9th September 2014

MBS Schedule 66560: Microalbumin

A/Prof Ken Sikaris 9th September 2014

MBS Schedule 66542: OGTT

A/Prof Ken Sikaris 9th September 2014

FPG vs 2hPG and diabetes.

6.1 7.0FPG (mmol/L)

IFG

7.8 11.1GLU-2h (mmol/L)

IGT

or

Diabetesnormal

and

5.5

(GDM 5.1)

A/Prof Ken Sikaris 9th September 2014

Gestational Diabetes

A/Prof Ken Sikaris 9th September 2014

MBS Schedule 66545: Glucose Challenge Test Pregnancy

A/Prof Ken Sikaris 9th September 2014

MBS Schedule 66545: Oral Glucose Tolerance Test in Pregnancy

A/Prof Ken Sikaris 9th September 2014

MBS Schedule 66554: HbA1c pregnancy

A/Prof Ken Sikaris 9th September 2014

New GDM Criteria

• ADIPS 1999-2014

– Prevalence 8%

• IADPSG (HAPO)

– Projected Prevalence 14%

• Optimal Glucose sample (fluoride-ice/citrate)

–Potential Prevalence 20%

»Same as HAPO

A/Prof Ken Sikaris 9th September 2014

ADA Working Party Report Diabetes Care 2009; 32: 1327-34

ADA recommends: HbA1c 6.5% for diagnosis of diabetes

Pre

va

len

ce

of

retin

op

ath

y

A/Prof Ken Sikaris 9th September 2014

Stroke

(Exp

on

en

tia

l)

A/Prof Ken Sikaris 9th September 2014

All causes of mortality

(Exp

on

en

tia

l)

A/Prof Ken Sikaris 9th September 2014

ABS Survey 2011-12: Chronic Disease

Cancer Diabetes

Heart Disease

A/Prof Ken Sikaris 9th September 2014

ABS Survey 2011-12: Chronic Disease

Cancer

Diabetes

Heart Disease

A/Prof Ken Sikaris 9th September 2014

0.4

1.8

0.4

0.7

1.4

0.4

0.8

1.6

0.8

0.0

0.4

0.8

1.2

1.6

2.0

Normal Overweight Obese

Males

Females

All

Incidence of diabetes according to baseline body mass index

Baseline BMI status

Incid

en

ce (

% p

er

year)

Body mass index (BMI: weight/height2) was categorised into three groups: (i) normal: BMI < 25.0 kg/m2; (ii) overweight: 25.0─29.9 kg/m2; and (iii) obese: ≥ 30.0 kg/m2.

A/Prof Ken Sikaris 9th September 2014

Obesity in adults

A/Prof Ken Sikaris 9th September 2014

A/Prof Ken Sikaris 9th September 2014

Overweight children in Australia:

A/Prof Ken Sikaris 9th September 2014

Obesity in Babies ! Lack of Exercise?

Kim

et a

l, O

be

sity 2

00

6;1

5:1

107

.

A/Prof Ken Sikaris 9th September 2014

Changes in Dietary Composition

A/Prof Ken Sikaris 9th September 2014

A/Prof Ken Sikaris 9th September 2014

JAMA Intern Med. 2014;174(4):516-524. Added Sugar Intake and Cardiovascular Diseases Mortality Among US Adults Quanhe Yang, Zefeng Zhang, Edward W. Gregg, W. Dana Flanders, Robert Merritt, Frank B. Hu.

Prof Robert Lustig Auckland NZ Feb 2014

A/Prof Ken Sikaris 9th September 2014

A/Prof Ken Sikaris 9th September 2014

A/Prof Ken Sikaris 9th September 2014

A/Prof Ken Sikaris 9th September 2014

Insulin Resistance and Dyslipidemia

TGVLDL

(lipoprotein or hepatic lipase)

SDLDL

(CETP)

CE

HDL

TG

(hepaticlipase)

Kidney

Apo A-1(CETP)

LDL

TGCE

Liver

FFAFructose

A/Prof Ken Sikaris 9th September 2014

How small is sdLDL?

A/Prof Ken Sikaris 9th September 2014

A/Prof Ken Sikaris 9th September 2014

A/Prof Ken Sikaris 9th September 2014

Modified LDL is atherogenic

A/Prof Ken Sikaris 9th September 2014

A/Prof Ken Sikaris 9th September 2014

LDL gradient gel electrophoresis ‘Lipoprint’

A/Prof Ken Sikaris 9th September 2014

A/Prof Ken Sikaris 9th September 2014

Small Dense LDLAustin MA, King MC, Vranizan KM, Krauss RM, “Atherogenic lipoprotein

phenotype. A proposed genetic marker for coronary heart disease.”

Circulation 1990;82:495-506.

0.5 1.0 1.5 2.0 2.5 3.0

(mmol/L)

A/Prof Ken Sikaris 9th September 2014

Triglycerides

<0.5

0.5 to <1.0

1.0 to <1.5

1.5 to <2.0

2.0 to <2.5

2.5 to <3.0

3

Triglycerides (mmol/L)

0

500

1000

1500

2000

2500

3000

3500

Thou

sand

s of

Peo

ple

Men

Women

35% > 1.5 mmol/L

22% > 1.5 mmol/L

A/Prof Ken Sikaris 9th September 2014

Interpretation of blood fats• 30 years ago

– High cholesterol, Triglycerides unimportant

• 20 years ago– Bad cholesterol (LDLC), Good cholesterol (HDLC)

• 10 years ago– Modified LDL atherogenic

• Oxidised, Glycated, Apo(a)/Lp(a), Small Dense LDL)

• Today

– Triglycerides are important!– Move away from LDLC: Non HDLC = LDLC + VLDLC

A/Prof Ken Sikaris 9th September 2014

A/Prof Ken Sikaris 9th September 2014

Perspectives of Ken Sikaris.

A/Prof Ken Sikaris 9th September 2014

TIME® Magazine June 23rd 2014

A/Prof Ken Sikaris 9th September 2014

Professor Richard Johnson

A/Prof Ken Sikaris 9th September 2014

A/Prof Ken Sikaris 9th September 2014

Obesity versus Metabolic Dysfunction

240 million USA Adults

30% Obese

72 million

70% Normal

168 million

40% ‘Sick’

67 million

80% ‘Sick’

57 million

124 million USA Adults

Prof Robert Lustig Auckland NZ Feb 2014

A/Prof Ken Sikaris 9th September 2014

Prof Robert Lustig 2014 Conclusions;

Prof Robert Lustig Auckland NZ Feb 2014

A/Prof Ken Sikaris 9th September 2014

A/Prof Ken Sikaris 9th September 2014

‘That Sugar Film’ – Damon Gameau, January 2015

A/Prof Ken Sikaris 9th September 2014

Conclusions

• Pandemic in Obesity & Type 2 diabetes

– Increasing proportion of health costs

– Increasing proportion of Pathology

• Pathology has witnessed pandemic

– Diagnosed

– Monitored

– Prevented?

• Assist in focussing community on prevention

A/Prof Ken Sikaris 9th September 2014

Acknowledgements

• Inspiration

– Ms Louisa Sikaris